Arcturus Therapeutics Q2 EPS $(1.98) Misses $(0.21) Estimate, Sales $10.52M Miss $48.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics reported Q2 losses of $(1.98) per share, missing the analyst consensus estimate of $(0.21) by 842.86%. This is a 141.46% decrease over losses of $(0.82) per share from the same period last year. The company also reported quarterly sales of $10.52 million, missing the analyst consensus estimate of $48.50 million by 78.31%. This is a 61.17% decrease over sales of $27.09 million the same period last year.
August 07, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcturus Therapeutics reported a significant miss on both EPS and sales for Q2. EPS was $(1.98), missing estimates by 842.86%, and sales were $10.52M, missing estimates by 78.31%.
Arcturus Therapeutics reported a significant miss on both EPS and sales for Q2. The EPS was $(1.98), missing the consensus estimate of $(0.21) by a large margin of 842.86%. This is a significant decrease from the same period last year. The company also reported quarterly sales of $10.52 million, which missed the consensus estimate of $48.50 million by 78.31%. This is a significant decrease from the same period last year. These results are likely to have a negative impact on the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100